Louis P Garrison - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Louis P Garrison

Showing results (181-190 of 190) with videos related to

Pageof 19

Sort By:

You have reached the last page of results.This site can display upto 190 results.

Forum for Health Economics & Policy|November 8, 2024

Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best PracticesJason Shafrin, Jaehong Kim, Joshua T Cohen, et al.

Papillomavirus Research (Amsterdam, Netherlands)|November 29, 2017

Acceptability of cervical cancer screening using visual inspection among women attending a childhood immunization clinic in UgandaMeng Li, Agnes Nyabigambo, Patricia Navvuga, et al.

Health Policy (Amsterdam, Netherlands)|December 5, 2021

Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatmentsMonique Dabbous, Mondher Toumi, Steven Simoens, et al.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 26, 2018

A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]Louis P Garrison, Peter J Neumann, Richard J Willke, et al.

Journal of Medical Economics|June 11, 2025

Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United StatesLucio N Gordan, Arielle G Bensimon, Fan Mu, et al.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 28, 2021

Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?Abigail R Colson, Alec Morton, Christine Årdal, et al.

Vaccines|July 27, 2024

Capturing the Value of Vaccination within Health Technology Assessment and Health Economics-Practical Considerations for Expanding Valuation by Including Key ConceptsEliana Biundo, Mariia Dronova, Annie Chicoye, et al.

Health Policy OPEN|March 11, 2024

The evolving value assessment of cancer therapies: Results from a modified Delphi studyMyrto Lee, Hugo Larose, Martin Gräbeldinger, et al.

Pain|June 11, 2020

Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerationsShannon M Smith, Robert H Dworkin, Dennis C Turk, et al.

Pain|September 12, 2021

Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendationsBethea A Kleykamp, Robert H Dworkin, Dennis C Turk, et al.

Pageof 19

Search research articles

Showing results (181-190 of 190) with videos related to

Sort By:

Pageof 19

You have reached the last page of results.This site can display upto 190 results.

Forum for Health Economics & Policy|November 8, 2024

Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best PracticesJason Shafrin, Jaehong Kim, Joshua T Cohen, et al.

Papillomavirus Research (Amsterdam, Netherlands)|November 29, 2017

Acceptability of cervical cancer screening using visual inspection among women attending a childhood immunization clinic in UgandaMeng Li, Agnes Nyabigambo, Patricia Navvuga, et al.

Health Policy (Amsterdam, Netherlands)|December 5, 2021

Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatmentsMonique Dabbous, Mondher Toumi, Steven Simoens, et al.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 26, 2018

A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]Louis P Garrison, Peter J Neumann, Richard J Willke, et al.

Journal of Medical Economics|June 11, 2025

Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United StatesLucio N Gordan, Arielle G Bensimon, Fan Mu, et al.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 28, 2021

Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?Abigail R Colson, Alec Morton, Christine Årdal, et al.

Vaccines|July 27, 2024

Health Policy OPEN|March 11, 2024

The evolving value assessment of cancer therapies: Results from a modified Delphi studyMyrto Lee, Hugo Larose, Martin Gräbeldinger, et al.

Pain|June 11, 2020

Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerationsShannon M Smith, Robert H Dworkin, Dennis C Turk, et al.

Pain|September 12, 2021

Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendationsBethea A Kleykamp, Robert H Dworkin, Dennis C Turk, et al.

Pageof 19